Scripta Therapeutics
THE CHALLENGE
Oxford-based techbio startup Scripta Therapeutics had closed a $12 million seed funding round to build their innovative drug discovery platform.
It was time to come out of stealth mode and grab the world’s attention with an eye-catching brand, website, and PR campaign.
Scripta’s scientific approach – combining AI, cell imaging, and patient models to create and modulate disease maps based on transcriptional networks – was complex and tough to explain to non-specialists.
They also needed to stand out as distinctive and credible against a sea of similar-sounding ‘AI drug discovery’ companies.
OUR APPROACH
We worked together with our design partner Cohesion Labs to develop a bold visual and verbal brand identity for Scripta, together with distinctive narrative and messaging. The concept of “flipping the script on drug discovery” was deeply rooted in their science while setting them apart from similar companies in the techbio space.
We then brought their story to life by writing the copy for their eye-catching new website, which was designed and built by Cohesion. We also worked closely with the Scripta team to launch their blog on Substack, setting out their scientific manifesto and establishing a platform for future thought leadership.
Finally, we delivered an impactful PR campaign to announce their raise, attracting international media attention and generating several follow-up requests for articles and interviews. We also provided support on LinkedIn, which saw their company page grow from ~100 followers to more than 1700 within a month.
KEY RESULTS
Complex science made clear
A bold brand and memorable message
A successful launch with international media coverage
Grew from ~100 to >1700 LinkedIn followers in 1 month
WHAT THEY SAID
“Working with FCTM was a pleasure. They really helped us to create a compelling message and the perfect tone for our strategy, and delivered a PR campaign that put us on the map.”
FIND OUT ABOUT SOME OF OUR OTHER WORK
How we translated complex science into a high-value lead generation asset
Particology needed to grow their new business pipeline, and were looking for help communicating their highly technical science in a way that would help them stand out and showcase their expertise to their target audiences. They wanted a clear, professional marketing...
A bit of everything: Flexible, wide-ranging comms & marketing support for a growing life science company
Depixus first approached us in 2022 looking for help producing marketing materials that clearly articulated the technology and benefits of their highly innovative large-scale magnetic force spectroscopy platform for measuring individual biomolecular interactions. It...
Flexible, high-quality science content support for a busy marketing team
Biognosys is a leader in the proteomics space, providing cutting edge products and services to the global research community. As the business grew, so did the demand for high-quality content to increase brand awareness, generate leads, and drive sales. However, their...
Turning public opinions into compelling messaging
The Campaign for Science and Engineering (CaSE) believes that the UK should celebrate and invest in research and development (R&D). But without the public feeling the same way, R&D investment is unlikely to be a political priority. CaSE’s Discovery Decade...
Raising the profile of a rebellious research funder
Despite being the only UK research funder solely dedicated to ageing research The Dunhill Medical Trust (now the Vivensa Foundation) was struggling to reach their target grantee audiences, resulting in applications that weren’t quite the right fit. Following the...
Establishing our client as a biotech thought leader – and saving them £55k+ in the process
ERS Genomics manages and licenses the IP for CRISPR/Cas9 gene editing technology. While the technology itself is well known, far fewer people in the life sciences space are aware that they need to secure the appropriate licences to use it. ERS Genomics approached us...